(0.01%) 5 479.25 points
(0.00%) 38 819 points
(0.06%) 19 933 points
(0.29%) $80.56
(1.00%) $2.82
(0.12%) $2 331.70
(-0.39%) $29.28
(-0.10%) $969.90
(0.03%) $0.932
(-0.12%) $10.64
(0.09%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs...
Stats | |
---|---|
Šios dienos apimtis | 212 468 |
Vidutinė apimtis | 81 639 |
Rinkos kapitalizacija | 382.04M |
EPS | $-0.460 ( Q1 | 2024-01-31 ) |
Last Dividend | $0.130 ( 2015-02-02 ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.143 (1.68%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-30 | Bryce Richard Paul | Buy | 153 000 | Stock Option (Right to Buy) |
2023-11-30 | Daws D. Ryan | Buy | 232 000 | Stock Option (Right to Buy) |
2023-11-27 | Daws D. Ryan | Buy | 0 | |
2023-10-31 | Forbion Capital Fund Iii Cooperatief U.a. | Sell | 0 | Class A common shares |
2023-11-30 | Forbion Capital Fund Iii Cooperatief U.a. | Sell | 475 076 | Warrant (Right to Buy) |
INSIDER POWER |
---|
-38.61 |
Last 15 transactions |
Buy: 475 436 | Sell: 921 648 |
Tūris Koreliacija
enGene Holdings Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
enGene Holdings Inc. Koreliacija - Valiuta/Žaliavos
enGene Holdings Inc. Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
enGene Holdings Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.180 | 2012-04-02 |
Last Dividend | $0.130 | 2015-02-02 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 20 | -- |
Total Paid Out | $2.52 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
02 Feb 2015 | $0.130 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
01 Dec 2014 | $0.140 | 01 Dec 2014 | 30 Nov -0001 | 05 Dec 2014 |
03 Nov 2014 | $0.150 | 03 Nov 2014 | 30 Nov -0001 | 07 Nov 2014 |
01 Oct 2014 | $0.150 | 01 Oct 2014 | 30 Nov -0001 | 07 Oct 2014 |
01 May 2014 | $0.130 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
02 Dec 2013 | $0.120 | 29 Nov 2013 | 30 Nov -0001 | 06 Dec 2013 |
01 Nov 2013 | $0.120 | 01 Nov 2013 | 30 Nov -0001 | 07 Nov 2013 |
01 Oct 2013 | $0.120 | 01 Oct 2013 | 30 Nov -0001 | 07 Oct 2013 |
01 Aug 2013 | $0.120 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
01 May 2013 | $0.120 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
26 Dec 2012 | $0.110 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
03 Dec 2012 | $0.110 | 03 Dec 2012 | 30 Nov -0001 | 07 Dec 2012 |
01 Nov 2012 | $0.120 | 01 Nov 2012 | 30 Nov -0001 | 07 Nov 2012 |
01 Oct 2012 | $0.120 | 01 Oct 2012 | 30 Nov -0001 | 05 Oct 2012 |
04 Sep 2012 | $0.120 | 04 Sep 2012 | 30 Nov -0001 | 10 Sep 2012 |
01 Aug 2012 | $0.120 | 01 Aug 2012 | 30 Nov -0001 | 07 Aug 2012 |
02 Jul 2012 | $0.110 | 02 Jul 2012 | 30 Nov -0001 | 09 Jul 2012 |
01 Jun 2012 | $0.110 | 01 Jun 2012 | 30 Nov -0001 | 07 Jun 2012 |
01 May 2012 | $0.120 | 01 May 2012 | 30 Nov -0001 | 07 May 2012 |
02 Apr 2012 | $0.180 | 02 Apr 2012 | 30 Nov -0001 | 09 Apr 2012 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -1.105 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 8.55 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 12.97 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 12.57 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 12.40 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.263 | -1.500 | 5.62 | -8.44 | [0 - 0.6] |
interestCoverageTTM | -7.42 | 1.000 | -3.86 | -3.86 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.116 | 2.00 | -0.372 | -0.744 | [0 - 30] |
freeCashFlowPerShareTTM | -1.151 | 2.00 | -0.576 | -1.151 | [0 - 20] |
debtEquityRatioTTM | 0.393 | -1.500 | 8.43 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1.056 | 1.000 | -6.98 | -6.98 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 2.12 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.964 | 1.000 | -0.299 | 0 | [1 - 100] |
returnOnEquityTTM | 8.55 | 2.50 | 10.00 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.151 | 2.00 | -0.384 | -1.151 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.116 | 2.00 | -0.372 | -0.744 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0196 | 1.500 | -3.46 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | 0.0493 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
enGene Holdings Inc.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.